anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain an aerosol agent forming a sherbet-like foam gel to stably and persistently give a cooling effect, when sprayed in a quite new condition not indispensably requiring water, by using a specific raw liquid and a propellant. SOLUTION: This aerosol agent comprises a propellant and a raw liquid comprising a 1-3C lower alcohol and a nonionic surfactant. The aerosol agent is changed into a sherbet-like foam gel by the coagulation of the nonionic surfactant cooled with the evaporation heat of the liquidized gas. The lower alcohol, the surfactant and the liquid gas as the propellant are preferably compounded in amounts of 0.3-60 wt.%, 0.005-14 wt.% and 30-95 wt.%, respectively. The nonionic surfactant includes a polyoxyethylene alkyl ether and a polyoxyethyleneglycerol fatty acid ester. The propellant includes liquidized gases such as liquidized dimethyl ether and liquidized n-butane.
The invention discloses a medical image report generation method, a device, a storage medium and computer equipment, and relates to the technical field of medical data processing. The method comprises the following steps: acquiring medical image data and medical text data to be identified, performing feature extraction on the medical image data based on a pre-trained image feature extraction model to obtain image features, and performing feature extraction on the medical text data based on a pre-trained text feature extraction model to obtain text features. And then fusing the image features and the text features based on the pre-trained feature fusion model to obtain image-text fusion features. And classifying the image-text fusion characteristics through a pre-trained disease type classification module to obtain disease characteristics. And finally, generating a medical image report by utilizing a pre-trained report generation model according to the image-text fusion characteristics and the disease characteristics. The method can generate accurate and professional medical image reports and provide references for doctors to read.
BACKGROUND MRT4 Homolog, Ribosome Maturation Factor (MRTO4) is often upregulated in cancer cells. However, its impact in hepatocellular carcinoma (HCC) is less well understood. Herein, we explored the prognostic and energy metabolism reprogramming role of MRTO4 in HCC. MATERIAL AND METHODS Clinical data were obtained from The Cancer Genome Atlas (TCGA), and the expression of MRTO4 in clinical samples was analyzed. The association between different variables and overall survival (OS) was studied, as well as their potential as independent prognostic factors, using Cox regression analysis. We constructed a nomogram including clinical pathological variables and MRTO4 expression to provide a predictive model for prognosis. Heatmaps, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis revealed the relationship between energy metabolism pathways and MRTO4. We used classic molecular biology research methods, including RT-qPCR, Western blotting, CCK8, TUNEL, Clone formation, Transwell assay, ELISA, and immunohistochemistry, to study the role of MRTO4 in promoting the progression of HCC through glycolysis regulation. RESULTS Our study showed that MRTO4 is an independent prognostic risk factor for HCC and that MRTO4 accelerates glycolysis of HCC cells, promotes proliferation and invasion, and suppresses apoptosis of HCC cells. The underlying mechanism involves MRTO4 promoting glycolysis and accelerating HCC by inhibiting ALDOB. CONCLUSIONS Our study revealed a novel mechanism by which MRTO4 promotes glycolysis and accelerates HCC progression, and suggests that inhibiting MRTO4 could be a potential therapeutic strategy for HCC.
Concentrate for solution for infusion:

Oxaliplatin Injection, USP is supplied in clear, glass, single-dose vials containing 50 mg or 100 mg of oxaliplatin as a sterile, preservative-free aqueous solution at a concentration of 5 mg/mL. Tartaric Acid, NF, Water for Injection, USP and Sodium Hydroxide, NF are used as inactive ingredients and/or in combination as a buffering system.

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP controlled room temperature]. Do not freeze and protect from light (keep in original outer carton). Discard unused portion.

Oxaliplatin is a cytotoxic drug. Follow applicable special handling and disposal procedures.1 The use of gloves is recommended. If a solution of Oxaliplatin contacts the skin, wash the skin immediately and thoroughly with soap and water. If Oxaliplatin contacts the mucous membranes, flush thoroughly with water.
Described herein are compositions and techniques related to generation and therapeutic application of artificial synapses. Artificial synapses are engineered extracellular vesicles, including exosomes, which incorporate sticky binders on their surface to anchor signaling domains against biological targets, such as receptors. These engineered additives can be organized in genetic vector constructs, expressed in mammalian cells, wherein the sticky binders attach to extracellular vesicles such as exosomes, thereby presenting their joined signaling domains which are rapidly taken up by recipient cells. Artificial synapses adopt the hallmark biophysical and biochemical features of extracellular vesicles, allowing for rapid deployment and scale-up. Importantly, this strategy can allow for kinetically favorable signal generation and signal propagation. This includes, for example, increasing density of agonist presentation to support receptor clustering - an onerous barrier for traditional receptor targeting strategies.
A curvilinear endoscope is inserted orally and advanced to the duodenal bulb. Biliary accessibility is confirmed via EUS and with Doppler to rule out any intervening vessels. For common bile ducts \< 15 mm in diameter, the biliary access is established via needle puncture with a 19-gauge needle followed by advancement of a 0.035 or 0.025 inch guidewire. A LAMS (AxiosTM) will then be inserted with cautery assistance without tract dilation and deployed. For common bile ducts \> 15 mm, the need for initial needle puncture and wire insertion is at the discretion of the endoscopist. A cholangiogram is then performed through the LAMS with contrast injection. The choice of stent size will be at the discretion of the endoscopist (8 x 8 mm or 6 x 8 mm).
Patient will be dosed in GFH018 in combination with Toripalimab. In the PhaseIb part, the dose levels will be escalated following the Bayesian optimal interval (BOIN) design. In the Phase II part, patients will be assigned based on tumor type(s).
Systems, methods, operations, and devices are provided for creating medical charting recommendations. A system, method, operation, or device may provide a centralized universal data element repository that includes universal medical charting data elements. The system, method, operation, or device may also provide a medical charting build tool that enables clients to utilize the medical charting data elements. The system, method, operation, or device may also track particular universal medical charting data elements selected to display and to hide based on a patient's condition. The system, method, operation, or device may also provide access to a database administrator of the centralized universal data element repository to the universal medical charting data elements selected. The system, method, operation, or device may also create medical charting recommendations and enable modification.
The invention discloses isoquinoline-1,3(2H, 4H)-diketone containing isobutyric acid dimethyl ester groups and a preparation method and application thereof. The compound has the structure shown in the formula (I). The preparation method includes the steps that N-methacrylyl-N-alkylbenzene formamide serves as a substrate, dimethyl 2,2'-azobis(2-methylpropionate) serves as a free radical source, copper iodide serves as a catalyst, K3PO4 serves as alkali, DMF serves as a solvent, reaction is conducted in the air environment, reaction temperature is 90 DEG C, and the compound is obtained through column chromatography or thin-layer chromatography separation and purification after five hours of reaction. The compound shows a good inhibition effect on prostate cancer cells 22RV, some compounds obtained from the compound have good prospects in the aspect of prostatic cancer treatment, and a good opportunity is provided for fixing lead compounds for treating prostatic cancer. The synthesis reaction is easy to operate, a reaction system is mild, conditions are simple, cost is low, the yield is high, and the compound has great application and popularization value. Please see the formula (I) in the description.
Casein kinase II (CK2) has recently emerged as a pivotal mediator in the propagation of inflammation across various diseases. Nevertheless, its role in the pathogenesis of sepsis remains unexplored. Here, we investigated the involvement of CK2 in sepsis progression and the potential beneficial effects of silmitasertib, a selective and potent CK2α inhibitor, currently under clinical trials for COVID-19 and cancer. Sepsis was induced by caecal ligation and puncture (CLP) in four-month-old C57BL/6OlaHsd mice. One hour after the CLP/Sham procedure, animals were assigned to receive silmitasertib (50 mg/kg/i.v.) or vehicle. Plasma/organs were collected at 24 h for analysis. A second set of experiments was performed for survival rate over 120 h. Septic mice developed multiorgan failure, including renal dysfunction due to hypoperfusion (reduced renal blood flow) and increased plasma levels of creatinine. Renal derangements were associated with local overactivation of CK2, and downstream activation of the NF-ĸB-iNOS-NO axis, paralleled by a systemic cytokine storm. Interestingly, all markers of injury/inflammation were mitigated following silmitasertib administration. Additionally, when compared to sham-operated mice, sepsis led to vascular hyporesponsiveness due to an aberrant systemic and local release of NO. Silmitasertib restored sepsis-induced vascular abnormalities. Overall, these pharmacological effects of silmitasertib significantly reduced sepsis mortality. Our findings reveal, for the first time, the potential benefits of a selective and potent CK2 inhibitor to counteract sepsis-induced hyperinflammatory storm, vasoplegia, and ultimately prolonging the survival of septic mice, thus suggesting a pivotal role of CK2 in sepsis and silmitasertib as a novel powerful pharmacological tool for drug repurposing in sepsis.
PURPOSE: Multiple factors, such as dietary patterns, pharmaceutical interventions, and exposure to harmful substances, possess the capacity to influence gut microbiota composition. Gut microbiota dysbiosis has emerged as a significant contributor to the progression of chronic kidney disease (CKD) and its associated complications. By comprehending the intricacies of the intestinal microbiota, this research endeavor holds the potential to offer novel perspectives on potential strategies for mitigating CKD progression.
METHODS: In this retrospective analysis, we assessed gut microbiota composition in CKD patients. Fecal samples were collected from a cohort of 44 patients with stage 3-4 CKD, alongside a control group consisting of 132 healthy volunteers. Subsequently, 16 s rDNA sequencing was conducted to examine the composition of the gut microbiota.
RESULTS: Our findings revealed significant alterations in the diversity of intestinal microbiota in fecal samples between patients with stage 3-4 CKD and healthy subjects. Among the 475 bacterial genera, 164 were shared, while 242 dominant genera were exclusive to healthy subjects and 69 to CKD stages 3-4 samples. Notably, healthy volunteers exhibited a prevalence of intestinal Firmicutes and Bacteroidetes, whereas stage 3-4 CKD patients displayed higher abundance of Proteobacteria and Actinobacteria. The presence of uncultured Coprobacillus sp. notably contributed to distinguishing between the two groups. ROC curve analysis identified distinct microbiota with superior diagnostic efficacy for discriminating stage 3-4 CKD patients from healthy individuals. Metabolic pathway analysis revealed differing dominant pathways between the two groups-the NADH dehydrogenase pathway in healthy individuals and the phosphate acetyltransferase pathway in stage 3-4 CKD patients. Moreover, the CKD cohort displayed a higher proportion of Gram-negative bacteria and facultative anaerobes.
CONCLUSIONS: In conclusion, our study underscores the profound influence of gut microbiota dysbiosis on CKD progression. The distinct microbial profiles observed in CKD patients highlight the potential efficacy of microbiota-based interventions in mitigating CKD advancement.
The invention discloses an amphiphilic superparamagnetism magnetic resonance contrast medium and a preparation method thereof. The contrast medium takes MnFe2O4 nanometer grains as cores; polyalcohol The invention discloses an amphiphilic superparamagnetism magnetic resonance contrast medium and a preparation method thereof. The contrast medium takes MnFe2O4 nanometer grains as cores; polyalcoholmical compatibility, low toxicity and good stability. The preparation method has the advantages of simple operation, low cost, low requirements on the equipment, and easy realization of industrialiological compatibility, low toxicity and good stability. The preparation method has the advantages of simple operation, low cost, low requirements on the equipment, and easy realization of industrialized production.ized production.olecules evenly clad the surfaces of the MnFe2O4 nanometer grains; and part of hydroxies on the outer ends of the polyalcohol molecules react with 9-fluorenylmethyl chloroformate to form amphiphilicmolecules evenly clad the surfaces of the MnFe2O4 nanometer grains; and part of hydroxies on the outer ends of the polyalcohol molecules react with 9-fluorenylmethyl chloroformate to form amphiphilicshell structures through acyl chloride reactions. The preparation method comprises the following steps: taking the polyalcohol as a solvent, pyrolyzing ferric and manganese acetylacetonates at a highshell structures through acyl chloride reactions. The preparation method comprises the following steps: taking the polyalcohol as a solvent, pyrolyzing ferric and manganese acetylacetonates at a hightemperature to obtain the MnFe2O4 nanometer grains clad by the polyalcohol molecules through, and then carrying out the acyl chloride reaction between 9-fluorenylmethyl chloroformate and polyalcohol htemperature to obtain the MnFe2O4 nanometer grains clad by the polyalcohol molecules through, and then carrying out the acyl chloride reaction between 9-fluorenylmethyl chloroformate and polyalcohol hydroxies on the surfaces of the nanometer grains. The contrast medium has the advantages of small grain size, high crystallinity, high saturation magnetization rate, high relaxation capability, good bydroxies on the surfaces of the nanometer grains. The contrast medium has the advantages of small grain size, high crystallinity, high saturation magnetization rate, high relaxation capability, good biolog
Coronary heart disease (CHD) is a significant global health concern, particularly among the elderly. While care bundles present a comprehensive strategy for clinical disorders, their application in CHD rehabilitation remains understudied. This research addresses this gap by investigating the effectiveness of care bundles in CHD patients. By analyzing important performance degrees, we aim to contribute valuable insights to bridge existing knowledge deficiencies. Our study strives to establish a theoretical foundation for the broader implementation of care bundles, potentially improving the quality of care and patient outcomes in CHD rehabilitation. This is a retrospective study. 360 patients with CHD who were admitted to our hospital from January 2019 to October 2022 were enrolled in this retrospective study and divided into the observation group (n = 180) and control group (n = 180) according to the different care that they received. All cases were given routine nursing after CHD operation, and the observation group was given care bundles on the basis of the analysis of important performance degrees. The perioperative indexes, self-management ability score, depression, anxiety, stress scale (DASS), coping styles, medical compliance and the incidence of complications were compared between the 2 groups. Aftercare, the time of hospitalization and getting out-of-bed in the observation group was notably shorter (P < .05). Aftercare, the scores of self-management ability and related dimensions in the observation group were notably higher (P < .05). After care, the score of depression (P < .001), anxiety (P = .003) and stress (P = .017) of the observation group were notably lower. Aftercare, the observation group face score was significantly higher than the control group (P = .005), while the observation group avoidance score (P = .028) and yield score (P < .001) were significantly lower than the control group scores. Aftercare, the compliance behavior of patients in the observation group was notably better (P = .013). Aftercare, the incidence of complications in the observation group was notably lower (P = .039). Care bundles based on the degree of importance analysis can play a positive role in postoperative comorbid state, coping styles and self-management ability of patients with CHD, which can improve the rehabilitation effects on patients.
It has been hypothesized that dystonia may be a sensory disorder. Animal studies as well as physiological studies of patients with focal dystonia have demonstrated sensory dysfunction. It has also been shown that patients with dystonia have impaired sensory perception including when assessed with the JVP gap detection test. This could possibly result from enlargement and dedifferentiation of representations in the sensory cortex. We therefore hypothesize that sensory training could improve the impaired sensory perception and hence improve the dystonia. This study will examine if Braille reading as a sensory training program can correct the sensory perception and the dystonia. The primary outcome is improvement in the JVP gap detection test.
The present invention relates to a microneedle sheet cosmetic tool comprising a porous pad, which is capable of: making cosmetic components effectively penetrate into the skin; reducing the use of preservatives; and being applicable to a large area of the skin. The present invention is provide with an elastic layer in which microneedles are embedded. The microneedles may be made of a solid water-soluble polymer material. The elastic layer may contain solid water-soluble nutrients. The microneedles and the elastic layer may be provided by sequentially stacking an adhesive layer, a needle sheet, and an elastic layer on a base part. As the elastic layer contracts, the microneedles may protrude further and be applied to the skin. When a water-soluble solvent is supplied to the elastic layer, the solid water-soluble material is dissolved and supplied to the skin together with the water-soluble solvent.
INTRODUCTION: Hand hygiene (HH) plays a crucial role in mitigating healthcare-associated infections. Improving HH compliance in healthcare facilities in resource-limited settings is urgently needed.
METHODS: We implemented the World Health Organization (WHO) HH improvement strategy using a continuous quality improvement (CQI) approach targeting improvement in HH compliance by healthcare workers (HCWs). An intervention was implemented in six hospitals using a longitudinal study design between May 2019 and April 2023. We set up and monitored infection prevention and control (IPC) and HH programs using WHO's infection prevention and control assessment framework at the facility level (IPCAF) and hand hygiene self-assessment framework (HHSAF) tools. We implemented HH interventions using CQI techniques while targeting HCW HH knowledge and compliance with the WHO's Five Moments of HH.
RESULTS AND DISCUSSION: By the end of the intervention, IPC and HH capacity improved in all six hospitals, from a median score of 547.0 and 252.5 on IPCAF and HHSAF tools at baseline to an advanced score of 635.0 and 350.0 at endline assessment, respectively. Similarly, HCWs' HH knowledge improved in all hospitals, from a mean score of 45.0% at baseline to 76.0% at endline assessment, most notably among nurses. HH compliance, as assessed using WHO's HH observation tool, at least doubled in all hospitals, rising from 19.9% to 53.8%, with before touching a patient registering the highest (22-fold) improvement. On linear regression analysis, no significant association was observed between HH compliance and IPCAF b = -0.0004 (95% CI -0.093, 0.93) p = 0.990, HHSAF b = 0.009 (95% CI -.0127, 0.145) p = 0.842 and HCW knowledge on HH/IPC b = -0.165 (95% CI 0.815, 0.485) p = 0.519. This is the first documented comprehensive utilization of CQI approaches to implement HH as an entry point for the development of hospital IPC programs, and evaluation of WHO tools and approaches for IPC and HH improvement in Uganda.
CONCLUSION: Implementation of the WHO HH improvement strategy using a CQI approach can lead to remarkable improvement in HH capacity, and HCW compliance and knowledge in hospitals within resource-limited settings.
Drug: Apixaban 2.5 MG Participants will be given study medication at the time of discharge from the hospital. Participants will take Apixaban 2.5 MG twice a day, once in the morning and once in the evening, for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and contact will continue up to day 90 after starting study treatment. Follow up will be through electronic and/or telephone contact depending on the participant's preference, compliance, and medication adherence. Participants will be queried for any clinically relevant endpoints, especially major bleeding or a need to seek healthcare attention for any reason. Follow-up will occur from the time of discharge and through the 30 day study period, with contacts 2 days, 10 days, 20 days, and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
The experimental group will consist of the patients included in phase 3. These are the patients from the "after" phases i.e after the implementation of the algorithm.
Asbestos-Related Lung Cancer (ARLC) presents ongoing diagnostic challenges despite improved imaging technologies. The long latency period, coupled with limited access to occupational and environmental data along with the confounding effects of smoking and other carcinogens adds complexity to the diagnostic process. Compounding these challenges is the absence of a specific histopathologic or mutational signature of ARLC. A correlation between PD-L1 expression and response to immune checkpoint inhibition has not yet been proven. Thus, new biomarkers are needed to allow accurate diagnoses of ARLC, to enable prognostication and to offer personalized treatments. Liquid biopsies, encompassing circulating DNA and circulating tumor cells (CTCs), have gained attention as novel diagnostic methods in lung cancer to screen high-risk populations including those exposed to asbestos. CTCs can be enumerated and molecularly profiled to provide predictive and prognostic information. CTC studies have not been undertaken in populations at risk of ARLC to date. The potential of CTCs to provide real-time molecular insight into ARLC biology may significantly improve the diagnosis and management of ARLC patients.